Jiezhong Chen

Summary

Affiliation: University of Queensland
Country: Australia

Publications

  1. ncbi request reprint Medicinal importance of fungal beta-(1-->3), (1-->6)-glucans
    Jiezhong Chen
    Cancer Biology Program, Diamantia Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Queensland 4102, Australia
    Mycol Res 111:635-52. 2007
  2. ncbi request reprint Multiple signal pathways in the leukemogenesis and therapeutic implications
    Jiezhong Chen
    Cancer Biology Programme, Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
    Leuk Res 31:1759-60. 2007
  3. ncbi request reprint Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia
    Jiezhong Chen
    Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Australia
    Cancer Biol Ther 7:174-9. 2008
  4. ncbi request reprint Is Src the key to understanding metastasis and developing new treatments for colon cancer?
    Jiezhong Chen
    Cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, QLD, Australia
    Nat Clin Pract Gastroenterol Hepatol 5:306-7. 2008
  5. ncbi request reprint Biochemistry and molecular biology of exocellular fungal beta-(1,3)- and beta-(1,6)-glucanases
    Kirstee Martin
    Biotechnology Research Centre, La Trobe University, Bendigo, Victoria, Australia
    FEMS Microbiol Rev 31:168-92. 2007
  6. doi request reprint Comment on: dietary supplementation with laminarin, a fermentable marine beta (1-3) glucan, protects against hepatotoxicity induced by LPS in rat by modulating immune response in the hepatic tissue
    Jiezhong Chen
    Int Immunopharmacol 8:514-5; discussion 516-7. 2008

Collaborators

  • Kirstee Martin
  • Barbara M McDougall
  • Simon McIlroy
  • Robert J Seviour

Detail Information

Publications6

  1. ncbi request reprint Medicinal importance of fungal beta-(1-->3), (1-->6)-glucans
    Jiezhong Chen
    Cancer Biology Program, Diamantia Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Queensland 4102, Australia
    Mycol Res 111:635-52. 2007
    ..Careful choice of beta-glucan products is essential if their benefits are to be optimized, and a better understanding of how beta-glucans bind to receptors should enable more efficient use of their biological activities...
  2. ncbi request reprint Multiple signal pathways in the leukemogenesis and therapeutic implications
    Jiezhong Chen
    Cancer Biology Programme, Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
    Leuk Res 31:1759-60. 2007
  3. ncbi request reprint Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia
    Jiezhong Chen
    Diamantina Institute for Cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, Australia
    Cancer Biol Ther 7:174-9. 2008
    ..This review summarises the most recent progress in CLL with emphasis on molecular events and possible implications in therapy...
  4. ncbi request reprint Is Src the key to understanding metastasis and developing new treatments for colon cancer?
    Jiezhong Chen
    Cancer, Immunology and Metabolic Medicine, University of Queensland, Brisbane, QLD, Australia
    Nat Clin Pract Gastroenterol Hepatol 5:306-7. 2008
  5. ncbi request reprint Biochemistry and molecular biology of exocellular fungal beta-(1,3)- and beta-(1,6)-glucanases
    Kirstee Martin
    Biotechnology Research Centre, La Trobe University, Bendigo, Victoria, Australia
    FEMS Microbiol Rev 31:168-92. 2007
    ..It also updates the earlier review by Pitson et al. (1993)...
  6. doi request reprint Comment on: dietary supplementation with laminarin, a fermentable marine beta (1-3) glucan, protects against hepatotoxicity induced by LPS in rat by modulating immune response in the hepatic tissue
    Jiezhong Chen
    Int Immunopharmacol 8:514-5; discussion 516-7. 2008